Talphera (TLPH) Projected to Post Quarterly Earnings on Wednesday

Talphera (NASDAQ:TLPH) is expected to announce its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Talphera (NASDAQ:TLPH) last released its earnings results on Monday, March 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.90 on Wednesday. The company has a market capitalization of $46.86 million, a PE ratio of -2.44 and a beta of 0.79. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $1.01. Talphera has a fifty-two week low of $0.38 and a fifty-two week high of $1.57.

Analyst Ratings Changes

TLPH has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Westpark Capital started coverage on shares of Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 price objective for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Talphera currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Insider Buying and Selling

In related news, CFO Raffi Asadorian acquired 45,000 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were acquired at an average cost of $0.81 per share, for a total transaction of $36,450.00. Following the purchase, the chief financial officer owned 91,256 shares in the company, valued at approximately $73,917.36. The trade was a 97.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Shakil Aslam acquired 35,000 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were bought at an average price of $0.81 per share, for a total transaction of $28,350.00. Following the completion of the purchase, the insider owned 83,178 shares in the company, valued at approximately $67,374.18. This represents a 72.65% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 433,674 shares of company stock valued at $304,348 in the last 90 days. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Talphera

Hedge funds have recently made changes to their positions in the business. Group One Trading LLC raised its stake in shares of Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after purchasing an additional 29,500 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares during the period. Cantor Fitzgerald L. P. bought a new stake in shares of Talphera during the 4th quarter worth $658,000. Geode Capital Management LLC raised its stake in shares of Talphera by 107.0% during the 4th quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock worth $391,000 after purchasing an additional 177,294 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after purchasing an additional 207,166 shares during the period. 37.67% of the stock is currently owned by institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.